CAMBRIDGE, Mass.--(BUSINESS WIRE)--Jul 24, 2018--Sage Therapeutics (NASDAQ: SAGE), a clinical-stage biopharmaceutical company developing novel medicines to treat life-altering central nervous system (CNS) disorders, today announced that the company will host a conference call and live webcast on Tuesday, August 7, 2018 at 8:00 A.M. ET to report its second quarter 2018 financial results and to discuss recent business updates.

The live webcast can be accessed on the investor page of Sage's website at The conference call can be accessed by dialing 1-866-450-8683 (toll-free domestic) or 1-281-542-4847 (international) and using the conference ID 5396188. A replay of the webcast will be available on Sage's website approximately two hours after the completion of the event and will be archived for up to 30 days.

About Sage Therapeutics

Sage Therapeutics is a clinical-stage biopharmaceutical company committed to developing novel medicines to transform the lives of patients with life-altering CNS disorders. Sage has a portfolio of novel product candidates targeting critical CNS receptor systems, GABA A and NMDA. Sage's lead program, a proprietary IV formulation of brexanolone (SAGE-547), has completed Phase 3 clinical development for postpartum depression and a New Drug Application is currently under review with the U.S. Food and Drug Administration. Sage is developing its next generation modulators, including SAGE-217 and SAGE-718, in various CNS disorders. For more information, please visit

View source version on

CONTACT: Sage Therapeutics

Investor Contact:

Paul Cox, 617-299-8377


Media Contact:

Maureen L. Suda, 585-355-1134



SOURCE: Sage Therapeutics

Copyright Business Wire 2018.

PUB: 07/24/2018 06:30 AM/DISC: 07/24/2018 06:31 AM